Kaili Zheng, Chaoyong He, Guangming Chen, Huabin Wang, Yongjun Ma
{"title":"Glycemic control modifies LDL-C-DKD risk: a U-shaped association in well-controlled type 2 diabetes.","authors":"Kaili Zheng, Chaoyong He, Guangming Chen, Huabin Wang, Yongjun Ma","doi":"10.3389/fnut.2025.1660820","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The relationship between low-density lipoprotein cholesterol (LDL-C) levels and diabetic kidney disease (DKD) risk remains controversial, with limited evidence on its interaction with modifiable risk factors. This study aimed to investigate the dose-response relationship between LDL-C and DKD risk in patients with type 2 diabetes (T2D).</p><p><strong>Methods: </strong>A retrospective cohort of 3,040 patients with T2D without baseline DKD was followed. Association between LDL-C and DKD risk was analyzed using Cox regression analysis, interaction analysis, and restricted cubic splines (RCS). Sensitivity analyses excluded lipid-lowering medication users, and threshold effects were validated using piecewise regression and survival analysis.</p><p><strong>Results: </strong>A total of 665 (21.9%) patients developed DKD during the follow-up (median: 3.13 years). In the fully adjusted model, LDL-C as a continuous variable showed no significant association with DKD risk (<i>p</i> = 0.061). When analyzed by quartiles, the hazard ratios (HRs) displayed a non-monotonic pattern: Compared to Q1, Q2 had the lowest risk (HR = 0.69, <i>p</i> = 0.001), followed by a partial rebound in Q3 (HR = 0.80, <i>p</i> = 0.046), and a subsequent decline in Q4 (HR = 0.72, <i>p</i> = 0.005), suggesting potential non-linearity. A significant LDL-C-by-glycemia control interaction was observed (P<sub>interaction</sub> = 0.013). In the HbA1c ≤ 7% subgroup, RCS analysis demonstrated a U-shaped relationship between LDL-C and DKD risk (P<sub>non-linear</sub> < 0.001), with nadir risk observed at 2.66-3.57 mmol/L. The risk increased below 2.66 mmol/L (HR = 1.55, <i>p</i> = 0.015) and trended upward above 3.57 mmol/L (HR = 1.47, <i>p</i> = 0.121). In this subgroup, sensitivity analyses excluding lipid-lowering drug users confirmed robustness, and survival curves showed lower DKD incidence in the intermediate LDL-C group (2.66-3.57 mmol/L) vs. low/high groups (<i>p</i> = 0.004). No associations were found in the HbA1c > 7% subgroup.</p><p><strong>Conclusion: </strong>Glycemic control modulates the LDL-C-DKD risk association in patients with T2D, with a U-shaped relationship observed in those with good glycemic control, thereby emphasizing the necessity of integrating glycemic status into LDL-C target evaluations.</p>","PeriodicalId":12473,"journal":{"name":"Frontiers in Nutrition","volume":"12 ","pages":"1660820"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483909/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Nutrition","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.3389/fnut.2025.1660820","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The relationship between low-density lipoprotein cholesterol (LDL-C) levels and diabetic kidney disease (DKD) risk remains controversial, with limited evidence on its interaction with modifiable risk factors. This study aimed to investigate the dose-response relationship between LDL-C and DKD risk in patients with type 2 diabetes (T2D).
Methods: A retrospective cohort of 3,040 patients with T2D without baseline DKD was followed. Association between LDL-C and DKD risk was analyzed using Cox regression analysis, interaction analysis, and restricted cubic splines (RCS). Sensitivity analyses excluded lipid-lowering medication users, and threshold effects were validated using piecewise regression and survival analysis.
Results: A total of 665 (21.9%) patients developed DKD during the follow-up (median: 3.13 years). In the fully adjusted model, LDL-C as a continuous variable showed no significant association with DKD risk (p = 0.061). When analyzed by quartiles, the hazard ratios (HRs) displayed a non-monotonic pattern: Compared to Q1, Q2 had the lowest risk (HR = 0.69, p = 0.001), followed by a partial rebound in Q3 (HR = 0.80, p = 0.046), and a subsequent decline in Q4 (HR = 0.72, p = 0.005), suggesting potential non-linearity. A significant LDL-C-by-glycemia control interaction was observed (Pinteraction = 0.013). In the HbA1c ≤ 7% subgroup, RCS analysis demonstrated a U-shaped relationship between LDL-C and DKD risk (Pnon-linear < 0.001), with nadir risk observed at 2.66-3.57 mmol/L. The risk increased below 2.66 mmol/L (HR = 1.55, p = 0.015) and trended upward above 3.57 mmol/L (HR = 1.47, p = 0.121). In this subgroup, sensitivity analyses excluding lipid-lowering drug users confirmed robustness, and survival curves showed lower DKD incidence in the intermediate LDL-C group (2.66-3.57 mmol/L) vs. low/high groups (p = 0.004). No associations were found in the HbA1c > 7% subgroup.
Conclusion: Glycemic control modulates the LDL-C-DKD risk association in patients with T2D, with a U-shaped relationship observed in those with good glycemic control, thereby emphasizing the necessity of integrating glycemic status into LDL-C target evaluations.
期刊介绍:
No subject pertains more to human life than nutrition. The aim of Frontiers in Nutrition is to integrate major scientific disciplines in this vast field in order to address the most relevant and pertinent questions and developments. Our ambition is to create an integrated podium based on original research, clinical trials, and contemporary reviews to build a reputable knowledge forum in the domains of human health, dietary behaviors, agronomy & 21st century food science. Through the recognized open-access Frontiers platform we welcome manuscripts to our dedicated sections relating to different areas in the field of nutrition with a focus on human health.
Specialty sections in Frontiers in Nutrition include, for example, Clinical Nutrition, Nutrition & Sustainable Diets, Nutrition and Food Science Technology, Nutrition Methodology, Sport & Exercise Nutrition, Food Chemistry, and Nutritional Immunology. Based on the publication of rigorous scientific research, we thrive to achieve a visible impact on the global nutrition agenda addressing the grand challenges of our time, including obesity, malnutrition, hunger, food waste, sustainability and consumer health.